News - Appointments

Pierluigi Paracchi, co-founder and chief executive of Genenta Science srl, is one of two winners of the Lyfebulb-Helsinn Innovation award in oncology for work in discovering and developing cancer therapies with a potential for commercialisation.

Dan Furrer, an experienced sales executive, has been appointed head of corporate marketing at the Neuraxpharm Group, which specialises in treatments for disorders of the central nervous system.

Kiadis Pharma NV has promoted Dirk de Naeyer to the position of chief operations officer as it moves towards the commercialisation of its first product. Mr de Naeyer joined the Dutch company in October 2018 as head of the supply chain.

Pius Hornstein, an experienced Sanofi SA executive, has been promoted to the position of general manager China, the French company’s second largest market. Dr Hornstein was previously general manager for Brazil.

John Dellapa, a corporate lawyer, has become general counsel at Neurimmune AG of Switzerland having previously advised the neuroscience company on a number of global transactions.

Radu Aricescu is one of four people to join the new scientific advisory board of Confo Therapeutics NV, a Belgian company developing antibody fragments directed at G-protein coupled receptors (GPCRs).

Athanasios Papadopoulos, a former Sanofi SA executive, has joined Emergex Vaccines Holding Ltd as chief medical officer. Based in Oxford, UK, Emergex is working on a new approach to synthetic vaccine development. Dr Papadopoulos will oversee the company’s preclinical portfolio.

Joe Anderson has been reappointed chief executive officer of Arix Bioscience Plc, a healthcare investor, following a six-month period as the group’s chief investment officer. Dr Anderson is a former pharmaceutical analyst as well as a partner of Abingworth.

Anne Lane has been appointed managing director of UCL Business Plc (UCLB), the technology transfer arm of University College London (UCL). Dr Lane, who holds a PhD in medicine from UCL, joined the group in 2000.

Hookipa Pharma Inc has appointed former Amgen Inc executive Michael Kelly as an independent director to guide it through the development of its immunotherapy portfolio for infectious diseases and cancers. Mr Kelly is currently president of Sentry Hill Partners LLC consultancy.